CompletedPhase 2

Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma

Italy20 participantsStarted 2011-12

Plain-language summary

Phase II, monocentric, open label study to assess safety and activity of intralesional Rituximab for the treatment of indolent CD20+ lymphoma of conjunctiva.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * histological diagnosis of CD20+ B cell lymphoma subtypes: marginal zone lymphoma, grade 1-2 follicular lymphoma, plasmocytic lymphoma, small lymphocyte lymphoma * conjunctival localization alone (1EA stage; mono- or bilateral) * at least one measurable lesion * age \>/= 18 years * ECOG-PS \</=3 * HIV 1-2 negativity * at least one previous treatment (antibiotic or rituximab) Exclusion Criteria: * concomitant conventional (chemo-, radiation, immuno-), experimental (antibiotic) or corticosteroid anticancer therapy * known allergy to rituximab * systemic symptoms * concurrent diagnosis of pemphigus * postsurgical conjunctival scars

What they're measuring

assessment of safety

Timeframe: During experimental treatment (within 7 months from trial registration)

Trial details

NCT IDNCT01514344

SponsorAndres J. M. Ferreri

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2014-10

View on ClinicalTrials.gov More Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma trials